Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
http://dx.doi.org/10.25673/85978Langanzeige der Metadaten
| DC Element | Wert | Sprache |
|---|---|---|
| dc.contributor.author | Meyer, Hans-Jonas | - |
| dc.contributor.author | Wienke, Andreas | - |
| dc.contributor.author | Surov, Alexey | - |
| dc.date.accessioned | 2022-05-24T06:38:15Z | - |
| dc.date.available | 2022-05-24T06:38:15Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/87931 | - |
| dc.identifier.uri | http://dx.doi.org/10.25673/85978 | - |
| dc.description.abstract | Background: Low skeletal muscle mass (LSMM) and visceral fat areas can be assessed by cross-sectional images. These parameters are associated with several clinically relevant factors in various disorders with predictive and prognostic implications. Our aim was to establish the effect of computed tomography (CT)-defined LSMM and fat areas on unfavourable outcomes and in-hospital mortality in coronavirus disease 2019 (COVID-19) patients based on a large patient sample. Methods: MEDLINE library, Cochrane, and Scopus databases were screened for the associations between CT-defined LSMM as well as fat areas and in-hospital mortality in COVID-19 patients up to September 2021. In total, six studies were suitable for the analysis and included into the present analysis. Results: The included studies comprised 1059 patients, 591 men (55.8%) and 468 women (44.2%), with a mean age of 60.1 years ranging from 48 to 66 years. The pooled prevalence of LSMM was 33.6%. The pooled odds ratio for the effect of LSMM on in-hospital mortality in univariate analysis was 5.84 [95% confidence interval (CI) 1.07–31.83]. It was 2.73 (95% CI 0.54–13.70) in multivariate analysis. The pooled odds ratio of high visceral fat area on unfavourable outcome in univariate analysis was 2.65 (95% CI 1.57–4.47). Conclusions: Computed tomography-defined LSMM and high visceral fat area have a relevant association with in-hospital mortality in COVID-19 patients and should be included as relevant prognostic biomarkers into clinical routine. | eng |
| dc.description.sponsorship | Publikationsfonds MLU | - |
| dc.language.iso | eng | - |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
| dc.subject.ddc | 612 | - |
| dc.title | Computed tomography-defined body composition as prognostic markers for unfavourable outcomes and in-hospital mortality in coronavirus disease 2019 | eng |
| dc.type | Article | - |
| local.versionType | publishedVersion | - |
| local.bibliographicCitation.journaltitle | Journal of cachexia, sarcopenia and muscle | - |
| local.bibliographicCitation.volume | 13 | - |
| local.bibliographicCitation.issue | 1 | - |
| local.bibliographicCitation.pagestart | 159 | - |
| local.bibliographicCitation.pageend | 168 | - |
| local.bibliographicCitation.publishername | Wiley | - |
| local.bibliographicCitation.publisherplace | Hoboken, NJ | - |
| local.bibliographicCitation.doi | 10.1002/jcsm.12868 | - |
| local.openaccess | true | - |
| local.accessrights.dnb | free | - |
| Enthalten in den Sammlungen: | Open Access Publikationen der MLU | |
Dateien zu dieser Ressource:
| Datei | Beschreibung | Größe | Format | |
|---|---|---|---|---|
| J cachexia sarcopenia muscle - 2022 - Meyer - Computed tomography‐defined body composition as prognostic markers for.pdf | 989.77 kB | Adobe PDF | ![]() Öffnen/Anzeigen |
